Novo Nordisk, Hims & Hers settle GLP-1 drug dispute Kimberly Redmond 9, 2026// The basics: Novo Nordisk, Hims & Hers resolve GLP-1 drug lawsuit Wegovy, Ozempic to be offered on Hims & Hers platform Hims & Hers agrees to stop selling compounded semaglutide FDA-backed deal expands access to approved weight-loss drugs Novo Nordisk and Hims & Hers have ended a legal feud with an agreement that allows the telehealth platform to sell the pharma giants blockbuster brand-name GLP-1 drugs
This is still an ongoing area of research
The Loose Skin Question Loose skin comes down to the speed and size of weight loss, not the method
Every-other-weekly administration of BIO89-100 did not improve markers of glycemic control, with only the highest once-weekly dose showing a trend towards improvements (299)
La accin de la L-carnitina tapona el exceso de cidos grasos que no pueden ser usados, reduciendo la formacin de cuerpos cetnicos y estimulando la oxidacin de glucosa (Figura 2)
The FDA said companies have until May 22 to stop selling compounded versions of the drugs and stated that it could take legal action against companies that have sold unsafe copies of the drugs